Alzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Alzheimer's-Assc

More Like This

PR Newswire associated0

GLP-1 DRUG LIRAGLUTIDE MAY PROTECT AGAINST DEMENTIA

PR Newswire associated0

Alzheimer's Association Commends United Kingdom's Approval of Leqembi, But Condemns Decision to Deny NHS Access

Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile

PR Newswire associated0

RESEARCH ADVANCES FROM THE 2025 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE

New data on lecanemab to be presented at CTAD conference

61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals

BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD